Eric C. Jeschke
127 IP cases indexed. Covers patent matters.
Cases Presided Over
127 cases indexed | Page 3 of 5
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson and Omachron settled their PTAB inter partes review disputes, leading to termination of four IPRs covering Dyson vacuum technology patents. The settlement agreement is treated as confidential business information.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson and Omachron settled their inter partes review disputes before the PTAB instituted the trial, resulting in termination of the proceedings and confidentiality of the settlement agreement.
Honda Motor Co., Ltd. et al. v.Infogation Corp.
Honda and Infogation settled their dispute, prompting the PTAB to dismiss IPR2024-01160 before institution. The Board granted the joint motion to dismiss and ordered the settlement kept confidential.
Dyson Technology Limited et al. v.Omachron Intellectual Property Inc. et al.
Dyson and Omachron settled their inter partes review dispute over U.S. Patent 11,910,983 B2. The Board granted a joint motion to terminate the proceeding and treated the settlement agreement as confidential.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB denied Imperative Care’s petition to institute an IPR against Inari Medical’s U.S. Patent 11,744,691, finding no reasonable likelihood of success. The Board concluded the cited prior art did not disclose the required negative‑pressure pump configuration.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,011 B2 hemostasis valve patent after finding Imperative Care’s likelihood of success on at least one claim.
Eunsung Global Corp. v.HydraFacial LLC et al.
HydraFacial and Eunsung Global settled their IPR dispute before the Board could institute a trial. The joint motion to terminate was granted, and the settlement agreement was kept confidential.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB denied Imperative Care’s petition to review Inari Medical’s 11,744,691 patent covering catheter‑based embolism removal. The Board found the petitioner had not shown a reasonable likelihood of prevailing on any of the 31 challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s U.S. Patent 12,016,580 covering intravascular embolism treatment devices after finding Imperative Care’s obviousness arguments sufficiently promising.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable, finding anticipation and obviousness over Schaffer and its combinations with Hartley, Eller, and Garrison.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted inter partes review on all fifteen claims of Inari Medical’s ’005 patent, finding Imperative Care’s obviousness arguments against the hemostasis valve features sufficiently plausible.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,844,921 B2 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim. The dispute centers on the definition of “filament” and the applicability of Schaffer, Hartley, and Eller references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s 11,974,910 patent covering clot‑removal systems. Imperative Care successfully demonstrated a reasonable likelihood of unpatentability on multiple claims, prompting full‑scale review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,865,291 B2 hemostasis valve patent after Imperative Care showed a reasonable likelihood of success. All 16 challenged claims are now subject to trial.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted institution of an IPR against Inari Medical’s 11,969,333 patent covering intravascular clot‑removal systems. Petitioner Imperative Care showed a reasonable likelihood of success on at least one claim, prompting the Board to institute review on all challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted institution of an IPR on Inari Medical’s 12,109,384 patent covering hemostasis valves. All nine claims are under review based on anticipation and obviousness arguments centered on the Schaffer reference and related prior art.
Camel Manufacturing Company, LLC, d/b/a Camel Expeditionary v.DLX Enterprises LLC
Camel Manufacturing and DLX Enterprises entered a settlement that resolved all pending PTAB post‑grant review matters for patent 11,732,496. The Board granted the joint motion to terminate and treated the settlement documents as confidential business information.
Globus Medical, Inc. v.Spinelogik, Inc.
Globus Medical successfully petitioned the PTAB to challenge Spinelogik's spinal fusion implant patents. The Board found a reasonable likelihood of unpatentability based on anticipation and obviousness over prior art references like Blain. This decision advances the dispute into active trial proceedings.
Globus Medical, Inc. v.Spinelogik, Inc.
Globus Medical successfully navigated the PTAB institution phase against Spinelogik regarding spinal fusion implants. The Board found a reasonable likelihood of prevailing based on obviousness over Moskowitz and Steffee for several key claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care secured institution of an IPR against Inari Medical’s hemostasis‑valve patent covering claims 1‑9. The Board found a reasonable likelihood of unpatentability based on anticipation and obviousness over Schaffer and related references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. The review will cover claims 1‑9 and is based on anticipation and obviousness grounds over Schaffer, Hartley, and Eller references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that Imperative Care’s challenge to Inari Medical’s hemostasis valve patent succeeded, finding all nine claims unpatentable under §§ 102 and 103 based on prior‑art references Schaffer, Hartley, Eller, and Garrison.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis valve patent are unpatentable, finding anticipation and obviousness over Schaffer and combinations with Hartley, Eller, and Garrison.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable, finding anticipation and obviousness over Schaffer, Hartley, Eller and Garrison references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 B2 catheter aspiration patent after Imperative Care showed a reasonable likelihood of success on at least one claim. The review covers all 15 claims and four obviousness grounds involving Garrison, Schaffer, Hartley, and Eller references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care challenged Inari Medical’s 11,844,921 B2 hemostasis valve patent. The PTAB found a reasonable likelihood of unpatentability and instituted inter partes review on all 18 challenged claims.
Par-Kan Company, LLC et al. v.Unverferth Mfg. Co., Inc.
The PTAB denied Par-Kan Company's IPR against Unverferth Mfg. Co.'s patent 8967940, finding that the petitioner failed to demonstrate a reasonable likelihood of prevailing over prior art references like Morris and Hiniker Webpage.
Par-Kan Company, LLC et al. v.Unverferth Mfg. Co., Inc.
The PTAB denied the institution of an IPR challenging claims in a seed carrier patent (9745123). The Patent Owner successfully demonstrated that their prototype predated the prior art references cited by the Petitioner.
Decent Espresso International Ltd. v.DUVALL ESPRESSO IP ENFORCEMENT, LLC
Decent Espresso International Ltd. failed its IPR challenge against Duvall Espresso's brewing system patent, as the Board found insufficient evidence that the prior art rendered the invention obvious. The institution decision denied the petition, maintaining the validity of the core claims related to infused beverage preparation.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.